JP2012524248A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012524248A5 JP2012524248A5 JP2012505138A JP2012505138A JP2012524248A5 JP 2012524248 A5 JP2012524248 A5 JP 2012524248A5 JP 2012505138 A JP2012505138 A JP 2012505138A JP 2012505138 A JP2012505138 A JP 2012505138A JP 2012524248 A5 JP2012524248 A5 JP 2012524248A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- immunogenic composition
- lymphocytes
- activated
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 11
- 230000002163 immunogen Effects 0.000 claims 7
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims 5
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09305328 | 2009-04-17 | ||
| EP09305328.8 | 2009-04-17 | ||
| PCT/EP2010/054743 WO2010119003A1 (en) | 2009-04-17 | 2010-04-12 | Biomarker for monitoring patients |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012524248A JP2012524248A (ja) | 2012-10-11 |
| JP2012524248A5 true JP2012524248A5 (enExample) | 2013-05-30 |
| JP5661738B2 JP5661738B2 (ja) | 2015-01-28 |
Family
ID=42270292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012505138A Expired - Fee Related JP5661738B2 (ja) | 2009-04-17 | 2010-04-12 | 患者をモニターするためのバイオマーカー |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20120058493A1 (enExample) |
| EP (1) | EP2419728B1 (enExample) |
| JP (1) | JP5661738B2 (enExample) |
| KR (1) | KR20120027146A (enExample) |
| CN (1) | CN102395883B (enExample) |
| AU (1) | AU2010237215B2 (enExample) |
| BR (1) | BRPI1010512A2 (enExample) |
| CA (1) | CA2759050A1 (enExample) |
| CO (1) | CO6440591A2 (enExample) |
| CR (1) | CR20110513A (enExample) |
| CY (1) | CY1114910T1 (enExample) |
| DK (1) | DK2419728T3 (enExample) |
| ES (1) | ES2445146T3 (enExample) |
| HR (1) | HRP20140262T1 (enExample) |
| IL (1) | IL214917A (enExample) |
| MX (1) | MX2011010920A (enExample) |
| NZ (1) | NZ594896A (enExample) |
| PL (1) | PL2419728T3 (enExample) |
| PT (1) | PT2419728E (enExample) |
| RU (1) | RU2555340C2 (enExample) |
| SG (1) | SG175060A1 (enExample) |
| SI (1) | SI2419728T1 (enExample) |
| SM (1) | SMT201400046B (enExample) |
| TW (1) | TWI426270B (enExample) |
| WO (1) | WO2010119003A1 (enExample) |
| ZA (1) | ZA201107545B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6375947B2 (ja) * | 2012-05-11 | 2018-08-22 | 味の素株式会社 | 取得方法、評価装置、評価方法、評価プログラム、評価システムおよび端末装置 |
| US20140244556A1 (en) * | 2013-02-27 | 2014-08-28 | Abdul Saleh | Methods for and apparatus generating automated pharmaco genetics correlation |
| US20200353107A1 (en) * | 2017-12-08 | 2020-11-12 | Stc.Unm | In vivo imaging of tumor infiltration leukocytes |
| CN114859057A (zh) * | 2022-04-13 | 2022-08-05 | 江苏省中医院 | 人结直肠癌或人结直肠癌转移的预测性生物标志物及其应用 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| FR2643817B1 (fr) | 1989-03-06 | 1993-12-17 | Transgene Sa | Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus |
| DE3642912A1 (de) | 1986-12-16 | 1988-06-30 | Leybold Ag | Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer |
| US6054438A (en) | 1987-01-07 | 2000-04-25 | Imperial Cancer Research Technology Limited | Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin |
| FR2632863B2 (fr) | 1987-10-29 | 1990-08-31 | Transgene Sa | Virus du fowlpox recombinant et vaccins derives de ces virus |
| US5100587A (en) | 1989-11-13 | 1992-03-31 | The United States Of America As Represented By The Department Of Energy | Solid-state radioluminescent zeolite-containing composition and light sources |
| FR2668064B1 (fr) | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
| US5756102A (en) | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
| AU672359B2 (en) | 1991-03-07 | 1996-10-03 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US5179993A (en) | 1991-03-26 | 1993-01-19 | Hughes Aircraft Company | Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid |
| US6013638A (en) | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
| US6133028A (en) | 1993-05-28 | 2000-10-17 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| US5698443A (en) | 1995-06-27 | 1997-12-16 | Calydon, Inc. | Tissue specific viral vectors |
| US20030026782A1 (en) | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| EP0772619B2 (en) | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US6045802A (en) * | 1994-10-03 | 2000-04-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule |
| US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| FR2727689A1 (fr) | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| DE19520606B4 (de) | 1995-06-06 | 2004-04-08 | Roche Diagnostics Gmbh | Vorrichtung zur optischen Untersuchung von Oberflächen |
| EP1445322B2 (en) | 1995-06-15 | 2012-06-06 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| WO1998004727A1 (en) | 1996-07-25 | 1998-02-05 | Therion Biologics Corporation | Recombinant pox virus for immunization against tumor-associated antigens |
| FR2751879B1 (fr) | 1996-07-30 | 1998-10-30 | Transgene Sa | Composition pharmaceutique contre les tumeurs et infections a papillomavirus |
| AU727308B2 (en) | 1997-02-24 | 2000-12-07 | Dana-Farber Cancer Institute | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| FR2773885B1 (fr) | 1998-01-16 | 2000-03-03 | Elf Antar France | Methode de caracterisation de la capacite de neutralisation d'un lubrifiant et dispositif pour la mise en oeuvre de cette methode |
| JP3119228B2 (ja) | 1998-01-20 | 2000-12-18 | 日本電気株式会社 | 液晶表示パネル及びその製造方法 |
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| US6900049B2 (en) | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
| US20020037274A1 (en) | 1998-10-26 | 2002-03-28 | Angelica Williams | Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants |
| FR2787465A1 (fr) | 1998-12-21 | 2000-06-23 | Transgene Sa | Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes |
| ES2220448T3 (es) | 1999-02-04 | 2004-12-16 | Geron Corporation | Secuencias reguladoras de la transcripcion de la telomerasa transcriptasa inversa. |
| ATE332364T1 (de) | 1999-02-22 | 2006-07-15 | Transgene Sa | Verfahren zur gewinnung von purifizierter virenzuammensetzung |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| US7001596B1 (en) | 1999-11-15 | 2006-02-21 | Onyx Pharmaceuticals, Inc. | Oncolytic adenovirus |
| AUPQ520800A0 (en) | 2000-01-21 | 2000-02-17 | Alfred Hospital | Prime-boost vaccination strategy |
| DE20122302U1 (de) | 2000-11-23 | 2005-02-24 | Bavarian Nordic A/S | Variante des Modifizierten Vaccinia-Ankara-Virus |
| FI116851B (fi) * | 2001-05-03 | 2006-03-15 | Fit Biotech Oyj Plc | Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita |
| GB0118532D0 (en) | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
| US20040133243A1 (en) | 2002-07-26 | 2004-07-08 | Santamore William P. | Cardiac rhythm management system with intramural myocardial pacing leads and electrodes |
| MXPA05004588A (es) | 2002-10-29 | 2005-12-14 | Coley Pharmaceutical Group Ltd | Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c. |
| FR2862648B1 (fr) | 2003-11-21 | 2006-02-03 | Biomerieux Sa | Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c |
| ES2526344T3 (es) * | 2005-06-28 | 2015-01-09 | Oncothyreon Inc. | Método para el tratamiento de pacientes con una vacuna de glicoproteína mucinosa (MUC-1) |
| CN101541342A (zh) * | 2006-12-05 | 2009-09-23 | 特朗斯吉有限公司 | 产生提高的免疫应答的手段和方法 |
| BRPI0913108A2 (pt) * | 2008-05-29 | 2017-06-20 | Trangene S A | método ex-vivo para testar se um paciente responderá terapeuticamente a um método de tratamento, uso de níveis de células exterminadores naturais ativadas como um biomarcador, e, kit |
-
2010
- 2010-04-12 DK DK10719285.8T patent/DK2419728T3/da active
- 2010-04-12 PL PL10719285T patent/PL2419728T3/pl unknown
- 2010-04-12 RU RU2011146419/15A patent/RU2555340C2/ru not_active IP Right Cessation
- 2010-04-12 NZ NZ594896A patent/NZ594896A/xx not_active IP Right Cessation
- 2010-04-12 AU AU2010237215A patent/AU2010237215B2/en not_active Ceased
- 2010-04-12 CN CN201080016800.2A patent/CN102395883B/zh not_active Expired - Fee Related
- 2010-04-12 SG SG2011072360A patent/SG175060A1/en unknown
- 2010-04-12 EP EP10719285.8A patent/EP2419728B1/en not_active Not-in-force
- 2010-04-12 KR KR1020117024190A patent/KR20120027146A/ko not_active Abandoned
- 2010-04-12 WO PCT/EP2010/054743 patent/WO2010119003A1/en not_active Ceased
- 2010-04-12 CA CA2759050A patent/CA2759050A1/en not_active Abandoned
- 2010-04-12 HR HRP20140262AT patent/HRP20140262T1/hr unknown
- 2010-04-12 PT PT107192858T patent/PT2419728E/pt unknown
- 2010-04-12 ES ES10719285.8T patent/ES2445146T3/es active Active
- 2010-04-12 BR BRPI1010512A patent/BRPI1010512A2/pt not_active IP Right Cessation
- 2010-04-12 MX MX2011010920A patent/MX2011010920A/es active IP Right Grant
- 2010-04-12 US US13/264,946 patent/US20120058493A1/en not_active Abandoned
- 2010-04-12 JP JP2012505138A patent/JP5661738B2/ja not_active Expired - Fee Related
- 2010-04-12 SI SI201030533T patent/SI2419728T1/sl unknown
- 2010-04-16 TW TW099112032A patent/TWI426270B/zh not_active IP Right Cessation
-
2011
- 2011-09-01 IL IL214917A patent/IL214917A/en not_active IP Right Cessation
- 2011-09-29 CR CR20110513A patent/CR20110513A/es unknown
- 2011-10-14 ZA ZA2011/07545A patent/ZA201107545B/en unknown
- 2011-10-14 CO CO11136970A patent/CO6440591A2/es not_active Application Discontinuation
-
2014
- 2014-01-08 US US14/150,503 patent/US20140141039A1/en not_active Abandoned
- 2014-02-13 CY CY20141100110T patent/CY1114910T1/el unknown
- 2014-04-03 SM SM201400046T patent/SMT201400046B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bienkowska et al. | Cancer-associated fibroblasts in oral cancer: a current perspective on function and potential for therapeutic targeting | |
| KR102723248B1 (ko) | 펩타이드 백신 | |
| Liu et al. | Tollip orchestrates macrophage polarization to alleviate intestinal mucosal inflammation | |
| NZ591137A (en) | Methods and systems for predicting response of cells to a therapeutic agent | |
| JP2012533322A5 (enExample) | ||
| MX347871B (es) | Biomarcadores de citoquina como marcadores predictivos de respuesta clínica para acetato de glatirámero. | |
| JP2014503593A5 (enExample) | ||
| JP2014523920A5 (enExample) | ||
| JP2012524248A5 (enExample) | ||
| JP2016527202A5 (enExample) | ||
| JP2014521070A5 (enExample) | ||
| Huart et al. | Could protons and carbon ions be the silver bullets against pancreatic cancer? | |
| RU2011146419A (ru) | Биомаркер для мониторинга пациентов | |
| NZ621352A (en) | Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence | |
| JP2010514421A5 (enExample) | ||
| Fu et al. | Heparanase DNA vaccine delivered by electroporation induces humoral immunity and cytoimmunity in animal models | |
| WO2011073905A8 (en) | Novel tumor markers | |
| Sofra et al. | A Review of COVID-19 associated factors: CRP, Creatinine, Bilirubin, VLDL, HDL, Triglycerides, Cortisol and Thyroid Function | |
| JP2010510495A5 (enExample) | ||
| Poppe et al. | Combination of HDAC inhibition and cytokine enhances therapeutic HPV vaccine therapy | |
| JP2015503106A5 (enExample) | ||
| Kadriyan et al. | The Comparison of Exosome RNA Concentration and its LMP-1 and p53 content Among Patients with Nasopharyngeal Cancer before and after Chemoradiation | |
| Van Loo et al. | 5 proffered paper: the life history of 21 breast cancers | |
| Casse et al. | Current Immunotherapy Treatments and Researches Regarding HPV-Positive HNSCC, a Revue of the Literature | |
| Kwok et al. | EXTH-52. Spatially Resolved Antigenic Landscapes In Low-grade Glioma Reveal Targets For Personalized Immunotherapy |